ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
Company: ENDRA Life Sciences Inc.
Filing Date: December 19, 2019
Reporting Period: Event date of December 19, 2019
Context: The Company, an emerging growth company, entered into a Securities Purchase Agreement to conduct a private placement offering of Series B Convertible Preferred Stock and warrants to accredited investors.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $405,000.
- Securities Issued: 351.711 shares of Series B Convertible Preferred Stock and warrants exercisable for 426,316 shares of Common Stock.
- Preferred Stock Terms:
- Issue Price: $1,000 per share.
- Dividend Rate: 6.0% per annum (accrued, payable if declared).
- Conversion Price: $0.99 per share of Common Stock.
- Liquidation Preference: Pari passu with Series A Preferred Stock.
- Warrant Terms:
- Exercise Price: $0.99 per share.
- Term: 5 years from closing.
- Forfeiture: Unexercised warrants may be forfeited if forced conversion conditions are met.
- Transaction Costs: Placement agent commission of approximately 8.0% of gross proceeds plus a warrant for 14,211 shares of Common Stock.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Agreements
The filing reports the entry into a Material Definitive Agreement (Item 1.01) and Unregistered Sales of Equity Securities (Item 3.02). Key changes include:
- Capital Structure: Issuance of new Series B Convertible Preferred Stock with rights substantially similar to Series A, differing primarily in conversion and trading price triggers.
- Registration Rights: Investors joined an existing Registration Rights Agreement. The Company must file a registration statement within 30 days of the December 11, 2019 Series A closing to cover the resale of these securities.
- Penalty Provision: If the registration statement is not filed within the required timeframe, the Company must make pro rata payments to holders equal to 1.0% of the aggregate amount invested for each 30-day period of delay.
Outlook, Risks, and Contingencies
- Forced Conversion: The Company has the right to force conversion of Preferred Stock and forfeiture of Warrants if the 10-day volume-weighted average price of Common Stock exceeds $1.98 and a registration statement is effective.
- Liquidity Risk: The securities were sold under Section 4(a)(2) and Rule 506(b) exemptions and are not registered. They cannot be resold in the U.S. absent registration or an applicable exemption.
- Dilution: The offering includes warrants and convertible stock that will increase the number of outstanding shares upon exercise or conversion.
Investor Verification Checklist
- Verify the exact number of shares issued (351.711) and the total gross proceeds ($405,000) against the final closing statement.
- Confirm the filing status of the Registration Statement required within 30 days of the December 11, 2019 closing to avoid 1.0% penalty payments.
- Review the Certificate of Designations (Exhibit 4.1) for specific details on dividend accrual and liquidation preferences.
- Monitor the Common Stock trading price relative to the $1.98 forced conversion trigger.
- Check for any subsequent filings regarding the effectiveness of the registration statement for the resale of these securities.